CABA 주가 차트
CABA 주가 예측
Cabaletta Bio Inc
$4.15
8.35%
$0.32
종가: May 05, 16:00:00 GMT-4
$4.22
1.7%
$0.07
프리마켓: May 06, 06:20:07 GMT-4
뒤로
Cabaletta Bio Inc (CABA) 주가 예측
주요 통계
이전 종가
$3.83
시가
$3.8
일일 범위
$3.68 - $4.22
52주 범위
$1.11 - $4.22
거래량
9.0M
평균 거래량
2.6M
배당수익률
--
EPS(TTM)
-2.28
시가총액
$469.8M
CABA란 무엇인가요?
Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. The company is headquartered in Philadelphia, Pennsylvania and currently employs 148 full-time employees. The company went IPO on 2019-10-25. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). Resecabtagene autoleucel, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
